Taken together, our findings demonstrate that RF- and XGBoost-featured SCG5 is a circulating diagnostic indicator of PAC that may be a pathophysiological and systemic regulator for adiposity and can be a novel therapeutic target for both adipose tissue-wasting (e.g., cachexia, adipopenia, lipodystrophy, etc.)and accumulating diseases (e.g., obesity). The gene discussed is SCG5; the disease is lipodystrophy.